Citigroup
LUCD icon

Citigroup’s Lucid Diagnostics LUCD Stock Holding History

Citigroup’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.7K Buy
69,793
+65,376
+1,480% +$70.5K ﹤0.01% 4838
2026
Q1 		$5.08K Buy
4,417
+2,377
+117% +$3.02K ﹤0.01% 5262
2025
Q4 		$2.22K Sell
2,040
-1,933
-49% -$2.16K ﹤0.01% 5440
2025
Q3 		$4.01K Sell
3,973
-19,834
-83% -$21.7K ﹤0.01% 5295
2025
Q2 		$27.4K Buy
+23,807
New +$30.7K ﹤0.01% 5006
2022
Q3 		– Sell
-48
Closed – – 6119
2022
Q2 		$0 Sell
48
-650
-93% -$1.44K ﹤0.01% 6478
2022
Q1 		$2K Sell
698
-1,653
-70% -$6.04K ﹤0.01% 6072
2021
Q4 		$13K Buy
+2,351
New +$19.1K ﹤0.01% 5509

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Citigroup's LUCD Position: Q2 2026 in Review

Citigroup increased its Lucid Diagnostics (LUCD) stake by 1,480% in Q2 2026, buying an estimated $70.5K and bringing the position to 69,793 shares worth $74.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4838.

Citigroup first reported a position in LUCD in Q4 2021 and has held it in 8 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Citigroup held 69,793 shares of Lucid Diagnostics worth $74.7K as of Q2 2026.
  • Citigroup bought 65,376 Lucid Diagnostics shares in Q2 2026, an estimated $70.5K.
  • Lucid Diagnostics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4838 holding.
  • Citigroup first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 8 quarters since.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.